AMGEN TAKES ACTION WITH THE U.S. GOVERNMENT TO LOWER THE COST OF MEDICINES FOR AMERICAN PATIENTS

Core Insights - Amgen is actively collaborating with the U.S. government to reduce medicine costs for American patients while maintaining its commitment to innovation [1][2] - The company has expanded its direct-to-patient program, AmgenNow, offering significant discounts on certain medications [3] Investment and Manufacturing - Since 2018, Amgen has invested over $40 billion in U.S. manufacturing and research and development, supported by favorable tax policies [4] - In 2025, Amgen announced an additional $2.5 billion in U.S. manufacturing capital investments, including $900 million in Ohio and $1 billion in North Carolina [5] Recognition and Market Position - Amgen has been recognized as one of the "World's Most Innovative Companies" and "America's Best Large Employers" [7] - The company is part of the Dow Jones Industrial Average and the Nasdaq-100 Index, highlighting its significant market presence [7]